Munich, Germany, April 02, 2013: SuppreMol GmbH, a privately held biopharmaceutical company
developing novel therapies for the treatment of autoimmune diseases, today announced the
appointment of Dr. Klaus Schollmeier as Chief Executive Officer (CEO) of the Company with effect
April 1st, 2013. Dr. Schollmeier succeeds Prof. Dr. Peter Buckel, who resigns as CEO having reached
Dr. Schollmeier has more than 25 years of successful international management experience in the
pharmaceutical and biotech industry as well as in investment banking. Dr. Schollmeier led Santhera
Pharmaceuticals AG as CEO since the company’s foundation in 2004 and acts as Chairman of the
Board since October 2011. Previously, he was Managing Director Healthcare / Biotechnology at ING
BHF-Bank. Before this, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott.
His scientific responsibilities included head of oncology/immunology research at BASF’s central
laboratories in Germany, and senior director of biotechnology at BASF Bioresearch Corporation in
Cambridge, US. His business functions included General Manager of BASF Pharma Netherlands and
Vice President and General Manager for Western Europe. Mr. Schollmeier holds a Ph.D. in Biology
from the University of Düsseldorf, Germany.
Dr. Thomas Hecht, Chairman of the Advisory Board of SuppreMol GmbH, said: "We are very pleased
to have Dr. Schollmeier joining our Company at a time when SuppreMol is entering a new and exciting
phase. The Company has a very promising product candidate for the treatment of autoimmune
diseases in phase II clinical development with important clinical and regulatory milestones ahead. Dr.
Schollmeier will bring the necessary experience to the Company to advance SuppreMol’s products
towards a BLA (Biologics License Application)." Dr. Hecht added: "On behalf of the Board I would like
to thank Prof. Dr. Peter Buckel for his long-standing commitment to the success of SuppreMol and his
valuable contributions in building the company over the past years."
“I look forward to leading SuppreMol in the exciting years to come. SuppreMol’s product candidates
are based on innovative science and have shown promising data in early clinical trials ," stated Dr.
Klaus Schollmeier, the Chief Executive Officer of SuppreMol GmbH. “I will lead the corporate and
commercial development of SuppreMol in the years to come with the ambition to successfully advance
the key assets, in particular the lead program SM101. ”
SuppreMol GmbH is a privately held biopharmaceutical company developing novel therapeutics for the
treatment of autoimmune and allergic diseases. The company is pioneering the development of
soluble Fc-gamma receptors (Fc Rs), which are recombinant autologous therapeutic proteins with a
specific immunoregulatory potential. The company’s lead product SM101, a recombinant soluble
Fc RIIB is in phase II clinical development for the treatment of Primary Immune Thrombocytopenia
(ITP) and Systemic Lupus Erythematosus (SLE) and has potential to treat Rheumatoid Arthritis (RA)
and other autoimmune conditions. SuppreMol’s pipeline also includes two antibody development
programs utilizing the inhibitory effect of Fc RIIB suitable for alternative treatment strategies and
indications as well as an anti-IL-3 antibody to treat RA. SuppreMol was founded as a spin-off from the
laboratory of Prof. Dr. Robert Huber, Nobel Prize Laureate in Chemistry 1988, at the Max Planck
Institute for Biochemistry in Martinsried, Germany. To date SuppreMol has raised € 40.3 million
through private investors. Major shareholders in the company include MIG Fonds, BioMedPartners
AG, Santo Holding GmbH and FCP Biotech Holding GmbH along with KfW Mittelstandsbank , Bayern
Kapital GmbH, Max Planck Society, and Z-Cube.
Dr. Klaus Schollmeier
Chief Executive Officer
Tel: +49 89 30 90 50 680